Clinical Trial

Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy

Name: Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy — clinical trial record (NCT07256015)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy

Trial Details

NCT Number	NCT07256015
Lead Sponsor	Bristol-Myers Squibb
Conditions	Psoriasis
Enrollment	200 participants
Start Date	2025-08-05
Primary Completion	2027-07-05 (estimated)
Study Completion	2027-08-05 (estimated)
Updated on ClinicalTrials.gov	2025-12-01